| Last Updated On: |
Pharmaceutical Companies in India
Pharmaceutical, India's emerging industry, has appeared as the world leader in the fabrication of standard generic drugs, ever since the Patent Act 1970 permitted India to seriously approach and contribute in the pharmaceutical market worldwide.
Soon this industry will overtake the Manufacturing sector in India. Pharmaceutical Industry in India is world's forth largest industry by volume. India is the preferred nation for pharmaceutical generation, with low charges for research and development as well as production of drugs. And the pharmaceutical companies in India have made full use of the favorable environment offered by the country to make it big. The workforce and technological proficiency of pharmaceutical companies in India ensures the growth of the industry on a global scale as well as within India.
The sector attacked about $3100m growth with revenue in 2009-10, which witnessed an augmentation of 17% over 2009. Business observers predict that the Indian pharmaceutical market will escalate at an increasing mode as compared to the global pharmaceutical market, at a CAGR of 13.2% during the fiscal years 2009-14 to reach an overall worth of $15,490m in 2014.
India has also appeared as the preferred location for the pharmaceutical companies of the world because of its towering growth scenario furnished by elderly population, alteration in disease profile, developing patent system and socio-economic circumstances.
The competition in the Indian pharmaceutical market is cutthroat and the market is divided among the top 10 pharma companies accounting for 36.1% of the overall R&H sales in the fiscal year 2008.
India began to abide by the World Trade Organization's Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and acknowledged product rights after the revision of the Indian Patent Act in January 2005. Indian firms are laying out strategies to benefit from the Japanese government proposal to endorse generic drugs to minimize healthcare charges.
Top ten pharmaceutical companies in India
(along with their 2007 turnover):
Failure of the new patent system: Prerequisites associated with Sec 3(d) of the Patent (Amendment) Act 2005 restrict the copyright of an existing drug. Moreover, mandatory licensing permits Indian companies to keep producing generics of copyright products for overseas selling to underdeveloped nations.
Lack of proper infrastructure: Issues associated with regular power cuts and lack of suitable transport infrastructure will decelerate the expansion of the sector.
Inadequate funds: Restricted funding from FIs, venture capitalists and the government may decelerate the expansion of biotechnology sector in India.
Regulatory impediments: Rising of due meticulousness and conformity with product standards leads to high costs and interruption in the launch of new products.
Severe competition: Low margins and restricted capital to assist R&D is the result of intense pricing competition among local producers. This rivalry will further deepen from the joining in of the big drug companies in the Indian market to control the cost benefit and large reserve sources.
Lack of Professionals: A professional researcher needs atleast 8 years of education covering a range of specialties in order to qualify to work in biotech. And students have no patience to complete the studies for money, when they have lot many other options available.
Last Updated on 12/8/2011
Growth of Indian Pharmaceutical market
The sector attacked about $3100m growth with revenue in 2009-10, which witnessed an augmentation of 17% over 2009. Business observers predict that the Indian pharmaceutical market will escalate at an increasing mode as compared to the global pharmaceutical market, at a CAGR of 13.2% during the fiscal years 2009-14 to reach an overall worth of $15,490m in 2014.
The competition in the Indian pharmaceutical market is cutthroat and the market is divided among the top 10 pharma companies accounting for 36.1% of the overall R&H sales in the fiscal year 2008.
India began to abide by the World Trade Organization's Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and acknowledged product rights after the revision of the Indian Patent Act in January 2005. Indian firms are laying out strategies to benefit from the Japanese government proposal to endorse generic drugs to minimize healthcare charges.
Top ten pharmaceutical companies in India
(along with their 2007 turnover):
- Ranbaxy Laboratories
By sales India's largest pharma firm with the returns touching ` 4,198.96 crore (` 41.989 billion) in 2007 - Dr. Reddy's Laboratories
With a turnover of ` 4,162.25 crore (` 41.622 billion) in 2007, Dr Reddy's lab is second largest drug firm in India by sales . - Sun Pharmaceuticals
Sun Pharma Industries had an overall earnings of ` 2,463.59 crore (` 24.635 billion) in 2007. - Cipla
Cipla generated an annual revenue of ` 3,763.72 crore (` 37.637 billion) in 2007 making itself the third largest pharmaceutical firms. - Lupin Labs:
Lupin Labs yielded total profit of ` 2,215.52 crore (` 22.155 billion) in 2007. - Aurobindo Pharma
India's sixth largest pharma company by sales, Aurobindo posted ` 2,080.19 crore (` 20.801 billion) annual returns in 2007. - GlaxoSmithKlineg
With 2007 turnover touching ` 1,773.41 crore (` 17.734 billion, GSK is India's seventh largest pharma firm. - Cadila Healthcare
Cadila's earnings was ` 1,613.00 crore (` 16.13 billion) in the fiscal year 2007, establishing itself as India's eight largest drug company. - Aventis Pharma
With an annual revenue of ` 983.80 crore (` 9.838 billion) in 2007, Aventis Pharma has made a place for itself in the top ten pharma companies in India - Ipca Laboratories
Ipca is India's 10th largest pharma company by sales and in 2007 it had a turnover of ` 980.44 crore (` 9.804 billion)
Major issues concerning the pharmaceutical companies in India
Failure of the new patent system: Prerequisites associated with Sec 3(d) of the Patent (Amendment) Act 2005 restrict the copyright of an existing drug. Moreover, mandatory licensing permits Indian companies to keep producing generics of copyright products for overseas selling to underdeveloped nations.
Lack of proper infrastructure: Issues associated with regular power cuts and lack of suitable transport infrastructure will decelerate the expansion of the sector.
Inadequate funds: Restricted funding from FIs, venture capitalists and the government may decelerate the expansion of biotechnology sector in India.
Regulatory impediments: Rising of due meticulousness and conformity with product standards leads to high costs and interruption in the launch of new products.
Severe competition: Low margins and restricted capital to assist R&D is the result of intense pricing competition among local producers. This rivalry will further deepen from the joining in of the big drug companies in the Indian market to control the cost benefit and large reserve sources.
Lack of Professionals: A professional researcher needs atleast 8 years of education covering a range of specialties in order to qualify to work in biotech. And students have no patience to complete the studies for money, when they have lot many other options available.
Last Updated on 12/8/2011
Pharmaceutical Companies in India
